School of Life and Health Sciences, Zhejiang Chinese Medical University, Hangzhou, China.
School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
Cardiovasc Ther. 2022 Jun 28;2022:5978314. doi: 10.1155/2022/5978314. eCollection 2022.
Coronavirus disease 2019 (COVID-19) has been a global threat that pushes healthcare to its limits. Hypertension is one of the most common risk factors for cardiovascular complications in COVID-19 and is strongly associated with disease severity and mortality. To date, clinical mechanisms by which hypertension leads to increased risk in COVID-19 are still unclear. Furthermore, additional factors might increase these risks, such as the consideration of age and sex, which are of interest when in search of personalized treatments for hypertensive COVID-19 patients.
We conducted a retrospective cohort study of 543 COVID-19 patients in seven provinces of China to examine the epidemiological and clinical characteristics of COVID-19 in this population and to determine risk factors of hypertensive COVID-19 patients. We also used univariable and multivariable logistic regression methods to explore the risk factors associated with hypertensive COVID-19 patients in different age and sex subgroups.
Among the enrolled COVID-19 patients, the median age was 47 years (interquartile range (IQR) 34.0-57.0), and 99 patients (18.23%) were over 60 years old. With regard to comorbidities, 91 patients (16.75%) were diagnosed with hypertension, followed by diabetes, coronary disease, and cerebrovascular disease. Of the hypertensive COVID-19 patients, 51 (56.04%) were male. Multivariable analysis showed that old age, comorbid diabetes or coronary heart disease on admission, increased D-dimer, increased glucose, and decreased lymphocyte count were independent risk factors associated with hypertensive COVID-19 patients. Elevated total bilirubin (odds ratio [OR]: 1.014, 95% confidence interval [CI]: 0.23-1.05; = 0.043) and triglycerides (OR: 1.173, 95% CI: 0.049-1.617; = 0.007) were found to be associated with elderly hypertensive COVID-19 patients. In addition, we found that decreased lymphocytes, basophil, high-density lipoprotein, and increased fibrinogen and creatinine were related to a higher risk of disease severity in male patients. The most common abnormal clinical findings pertaining to female hypertensive COVID-19 patients were hemoglobin, total bile acid, total protein, and low-density lipoprotein.
Factors associated with increased risk of hypertensive COVID-19 patients were identified. Results to the different age and sex subgroups in our study will allow for better possible personalized care and also provide new insights into specific risk stratification, disease management, and treatment strategies for COVID-19 patients with hypertension in the future.
2019 年冠状病毒病(COVID-19)是对全球医疗保健的一次重大考验,其是一种全球性威胁。高血压是 COVID-19 心血管并发症的最常见危险因素之一,与疾病严重程度和死亡率密切相关。迄今为止,高血压导致 COVID-19 风险增加的临床机制仍不清楚。此外,其他因素可能会增加这些风险,例如考虑年龄和性别,在为高血压 COVID-19 患者寻找个性化治疗方法时,这些因素非常重要。
我们对中国七个省的 543 例 COVID-19 患者进行了回顾性队列研究,以检查该人群中 COVID-19 的流行病学和临床特征,并确定高血压 COVID-19 患者的危险因素。我们还使用单变量和多变量逻辑回归方法,探讨不同年龄和性别亚组中与高血压 COVID-19 患者相关的危险因素。
在纳入的 COVID-19 患者中,中位年龄为 47 岁(四分位距(IQR)34.0-57.0),99 例(18.23%)患者年龄大于 60 岁。就合并症而言,91 例(16.75%)患者被诊断为高血压,其次是糖尿病、冠心病和脑血管病。在高血压 COVID-19 患者中,51 例(56.04%)为男性。多变量分析表明,高龄、入院时合并糖尿病或冠心病、D-二聚体升高、血糖升高和淋巴细胞计数降低是与高血压 COVID-19 患者相关的独立危险因素。总胆红素升高(比值比[OR]:1.014,95%置信区间[CI]:0.23-1.05; = 0.043)和三酰甘油升高(OR:1.173,95%CI:0.049-1.617; = 0.007)与老年高血压 COVID-19 患者相关。此外,我们发现,淋巴细胞、嗜碱性粒细胞、高密度脂蛋白减少,纤维蛋白原和肌酐升高与男性患者疾病严重程度的风险增加相关。女性高血压 COVID-19 患者最常见的异常临床发现是血红蛋白、总胆汁酸、总蛋白和低密度脂蛋白。
确定了与高血压 COVID-19 患者风险增加相关的因素。我们对不同年龄和性别亚组的研究结果将有助于更好地进行个性化护理,并为未来高血压 COVID-19 患者的特定风险分层、疾病管理和治疗策略提供新的见解。